RecruitingPhase 2NCT05174611

Vitamin D to Improve Quadricep Muscle Strength

Vitamin D as an Intervention for Improving Quadricep Muscle Strength in Patients After Anterior Cruciate Ligament Reconstruction: A Randomized Double-Blinded, Placebo-Controlled Clinical Trial


Sponsor

Chinese University of Hong Kong

Enrollment

60 participants

Start Date

Mar 17, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Quadriceps muscle strength is one of the key determinants for patients to fulfill the Return-to-Play (RTP) criteria after an anterior cruciate ligament reconstruction (ACLR), in which the muscle size is directly linked to muscle strength. Quadriceps muscle atrophy is unavoidable after ACLR, but the rehabilitation program should increase quadriceps muscle mass. However, despite good rehabilitation compliance, some patient's progress is sub-par and fail to regain muscle mass. Quadriceps muscle atrophy can persist beyond the completion of the rehabilitation program in almost half the patients and the reason behind this is still unknown. This represents an area that requires significant investigation, as quadriceps muscle atrophy and weakness have been shown to be determinants of poor knee function, decreased performance in sports and increased risk of reinjury. Quadriceps muscle atrophy after ACLR is well documented. This can be due to a decreased ability to regain muscle mass with rehabilitation. Athletes are one of the high-risk groups for vitamin D insufficiencies. Vitamin D deficiency can potentially result in decreased hypertrophy when exercising the muscle, leading to a poorer outcome in rehabilitation. Vitamin D has long been recognized for its effect on musculoskeletal health. It can have a direct effect on muscle hypertrophy by acting on specific vitamin D receptors (VDRs) on myocytes, and sufficient or increased levels of vitamin D in patients have been found to correlate with an increase in the size, number, and strength of muscle fibres. Quadriceps muscle hypertrophy after ACLR is triggered by exercise training, facilitated by diet and a number of intrinsic factors. As the rehabilitation programs and diets are similar in patients with varying extents of quadriceps muscle atrophy, individual responses (intrinsic factors) to exercise training may account for the resulting persistent quadriceps muscle atrophy. In this study, the investigators hypothesize that the deficiency of vitamin D may contribute to persistent quadriceps atrophy and weakness. With a stringent double-blinded randomized-controlled-trial (RCT) research design, our proposal will then address the research questions: 'Does vitamin D supplements improve the vitamin D deficiency status in patients after ACL reconstruction?', and 'Does vitamin D supplements improve quadriceps muscle strength for patients after ACLR?'


Eligibility

Min Age: 18 YearsMax Age: 40 Years

Inclusion Criteria6

  • Aged 18-40 with unilateral ACL injury
  • Sporting injury with a Tegner score of 7
  • Pre-op serum vitamin D level \<20 ng/ml
  • months post-ACLR with serum Vitamin D level remained \<20ng/ml
  • LSI for quadriceps strength \<70% of contralateral leg at 4-month isokinetic assessment
  • Both knees without history of injury/prior surgery

Exclusion Criteria6

  • Concomitant bone fracture, major meniscus injury or full-thickness chondral injuries requiring altered rehabilitation program post-operatively
  • Pre-operative radiographic signs of arthritis
  • Metal implants that would cause interference on MRI
  • Non-HS graft for ACLR
  • Patient non-compliant to the rehabilitation program
  • Regular sunbed users

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTVitamin D3

Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.

OTHERPlacebo

Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.


Locations(1)

The Chinese University of Hong Kong

Hong Kong, Hong Kong

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05174611


Related Trials